A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis (CONSONANCE)

Conditions

Diseases of the Nervous System

Volunteers
Health Professionals

What is the purpose of this trial?

Brief Summary:

This study is a prospective, multicenter, open-label, single-arm effectiveness and safety study in participants with progressive multiple sclerosis (PMS).

Ages
18 years - 65 years
Gender
Both

Find out more about who can participate in this trial

Trial with
Genentech, Inc.
Start Date
05/18/2021
End Date
09/29/2023

For more information about this study, contact:

Dimitri Duvilaire

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

Volunteer Now

Principal Investigator

Erin Longbrake, MD/PhD
Assistant Professor of Neurology; Director, Fellowship Program, Multiple Sclerosis & Other Inflammatory Brain Disease

Last Updated
07/15/2021
Study HIC
#2000024074

A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis (CONSONANCE)

Conditions

Volunteers

Health Professionals

What is the purpose of this trial?

I'm interested in volunteering

Principal Investigator

Contact Information